670 related articles for article (PubMed ID: 15087669)
1. Grading ovarian serous carcinoma using a two-tier system.
Malpica A; Deavers MT; Lu K; Bodurka DC; Atkinson EN; Gershenson DM; Silva EG
Am J Surg Pathol; 2004 Apr; 28(4):496-504. PubMed ID: 15087669
[TBL] [Abstract][Full Text] [Related]
2. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
Shen XX; Yu L; Bi R; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
[TBL] [Abstract][Full Text] [Related]
4. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma.
Malpica A; Deavers MT; Tornos C; Kurman RJ; Soslow R; Seidman JD; Munsell MF; Gaertner E; Frishberg D; Silva EG
Am J Surg Pathol; 2007 Aug; 31(8):1168-74. PubMed ID: 17667538
[TBL] [Abstract][Full Text] [Related]
5. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study.
Bodurka DC; Deavers MT; Tian C; Sun CC; Malpica A; Coleman RL; Lu KH; Sood AK; Birrer MJ; Ozols R; Baergen R; Emerson RE; Steinhoff M; Behmaram B; Rasty G; Gershenson DM
Cancer; 2012 Jun; 118(12):3087-94. PubMed ID: 22072418
[TBL] [Abstract][Full Text] [Related]
6. Is the two-tier ovarian serous carcinoma grading system potentially useful in stratifying uterine serous carcinoma? A large multi-institutional analysis.
Ahmed Q; Hussein Y; Hayek K; Bandyopadhyay S; Semaan A; Abdul-Karim F; Al-Wahab Z; Munkarah AR; Elshaikh MA; Alosh B; Nucci MR; Van de Vijver KK; Morris RT; Oliva E; Ali-Fehmi R
Gynecol Oncol; 2014 Feb; 132(2):372-6. PubMed ID: 24262874
[TBL] [Abstract][Full Text] [Related]
7. FIGO Versus Silverberg Grading Systems in Ovarian Endometrioid Carcinoma: A Comparative Prognostic Analysis.
Parra-Herran C; Bassiouny D; Vicus D; Olkhov-Mitsel E; Cesari M; Ismiil N; Nofech-Mozes S
Am J Surg Pathol; 2019 Feb; 43(2):161-167. PubMed ID: 30212391
[TBL] [Abstract][Full Text] [Related]
8. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
Seidman JD; Horkayne-Szakaly I; Cosin JA; Ryu HS; Haiba M; Boice CR; Yemelyanova AV
Gynecol Oncol; 2006 Nov; 103(2):703-8. PubMed ID: 16828848
[TBL] [Abstract][Full Text] [Related]
9. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
[TBL] [Abstract][Full Text] [Related]
10. Validation of a two-tier grading system in an unselected, consecutive cohort of serous ovarian cancer patients.
Battista MJ; Cotarelo C; Almstedt K; Heimes AS; Makris GM; Weyer V; Schmidt M
Arch Gynecol Obstet; 2016 Sep; 294(3):599-606. PubMed ID: 26993518
[TBL] [Abstract][Full Text] [Related]
11. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
[TBL] [Abstract][Full Text] [Related]
12. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases.
Deavers MT; Gershenson DM; Tortolero-Luna G; Malpica A; Lu KH; Silva EG
Am J Surg Pathol; 2002 Sep; 26(9):1129-41. PubMed ID: 12218569
[TBL] [Abstract][Full Text] [Related]
13. Tumor recurrence in stage I ovarian serous neoplasms of low malignant potential.
Silva EG; Tornos C; Zhuang Z; Merino MJ; Gershenson DM
Int J Gynecol Pathol; 1998 Jan; 17(1):1-6. PubMed ID: 9475184
[TBL] [Abstract][Full Text] [Related]
14. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of two-tier grading system and significance of p53 protein over-expression in ovarian serous carcinoma].
Lin J; Du J; Zhang CY; Xie QT; Zhang B; Liu CR
Zhonghua Bing Li Xue Za Zhi; 2010 Oct; 39(10):655-60. PubMed ID: 21176529
[TBL] [Abstract][Full Text] [Related]
16. Clinically occult tubal and ovarian high-grade serous carcinomas presenting in uterine samples: diagnostic pitfalls and clues to improve recognition of tumor origin.
Bagby C; Ronnett BM; Yemelyanova A; Maleki Z; Kuhn E; Vang R
Int J Gynecol Pathol; 2013 Sep; 32(5):433-43. PubMed ID: 23896706
[TBL] [Abstract][Full Text] [Related]
17. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
19. Low-grade Serous Carcinoma of the Ovary: Clinicopathologic Analysis of 52 Invasive Cases and Identification of a Possible Noninvasive Intermediate Lesion.
Ahn G; Folkins AK; McKenney JK; Longacre TA
Am J Surg Pathol; 2016 Sep; 40(9):1165-76. PubMed ID: 27487741
[TBL] [Abstract][Full Text] [Related]
20. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma.
Djordjevic B; Malpica A
Am J Surg Pathol; 2012 Jul; 36(7):955-63. PubMed ID: 22613998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
